Lyra Therapeutics LYRA 深 沪
已收盘 12-19 16:00:00 美东时间
3.60
-0.120
-3.23%
华盛通- 最 高4.04
- 今 开3.935
- 成交量 4.20万股
- 最 低 3.56
- 昨 收 3.72
- 总市值 638.96万
- 52周最高 37.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.84
- 委 比 60.00%
- 总股本 177.49万
- 历史最高 1100.00
- 量 比 1.23
- 振 幅 12.90%
- 历史最低 3.56
- 每 手 1
- 风险率 3.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lyra Therapeutics Q3 EPS $(3.38) Beats $(5.25) Estimate, Sales $25.000K Miss $195.000K Estimate
Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(3.38) per share which beat the analyst consensus estimate of $(5.25) by 35.68 percent. This is a 62.44 percent increase over losses of $(9.00) per share from
11-13 05:37
Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Lyra Therapeutics plans a confirmatory Phase 3 trial for LYR-210 to treat chronic rhinosinusitis (CRS) without nasal polyps, advancing toward NDA submission. The company reported a net loss of $6.0 million in Q3 2025, with cash reserves of $22.1 million, sufficient to fund operations into Q3 2026. R&D expenses decreased by $1.9 million, while general and administrative expenses dropped by $1.7 million. LYR-210 aims to provide six months of anti-i...
11-12 21:01
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Genprex (NASDAQ:GNPX) stock increased by 88.1% to $0.47 during Wednesd...
10-15 20:09
Lyra Therapeutics Outlines Clinical Plan For LYR-210 Following FDA Meeting And Announces ENLIGHTEN 2 Late-Breaking Oral Presentation
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting
10-06 19:08
Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds
Upstream Bio's Phase 2 trial of verekitug in chronic rhinosinusitis met all endpoints, showing reduced nasal polyps, congestion, and need for surgery.
09-03 00:33
Lyra Therapeutics Receives Nasdaq Deficiency Letter
An update from Lyra Therapeutics ( ($LYRA) ) is now available. On August 20, 20...
08-23 04:53
Lyra Therapeutics Q2 EPS $(5.51) Beats $(6.02) Estimate, Sales $183.000K Beat $171.250K Estimate
Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(5.51) per share which beat the analyst consensus estimate of $(6.02) by 8.47 percent. This is a 85.01 percent increase over losses of $(36.76) per share from
08-13 04:19
Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Lyra Therapeutics announced strong Phase 3 results for LYR-210 in chronic rhinosinusitis (CRS), enabling business momentum and securing $5 million financing extending cash runway into Q3 2026. The ENLIGHTEN 2 trial met primary and secondary endpoints, with LYR-210 showing significant symptom improvement and safety. The company resumed manufacturing, engaged FDA discussions, and adjusted stock split to regain compliance. Second-quarter financials ...
08-12 20:01
Lyra Therapeutics registers shares for resale from warrant exercises
Lyra Therapeutics (NASDAQ:LYRA) registers 846,744 shares of common stock for resale by selling securityholders. Shares are issuable upon exercise of outstanding warrants; company will receive proceeds...
07-23 05:46
